REG - Medpal AI PLC - Pharmacy operations update

Medpal AIAnnouncement

Today 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260205:nRSE7665Ra&default-theme=true

RNS Number : 7665R  Medpal AI PLC  05 February 2026

5 February 2026

MedPal AI plc

("MedPal AI" or the "Company")

Pharmacy - Operational Update

 

 

MedPal AI (AIM: MPAL
(https://www.londonstockexchange.com/stock/MPAL/medpal-ai-plc/company-page) ,
FRA: Z1N
(https://live.deutsche-boerse.com/equity/medpal-ai-plc-ls-0002?mic=XFRA) ),
the AI-powered, integrated digital health company, is pleased to announce the
continued strong performance of automated pharmacy operations at its
wholly-owned subsidiary, MedPal Limited. MedPal AI combines its user-friendly
mobile app, AI-driven diagnosis and triage with human-in-the-loop clinical
oversight and prescribing services, with high-tech robotic pharmacy
dispensing.

 

January 2026 Dispensing Performance

The Company is pleased to report that its pharmacy operations dispensed 36,951
items during January 2026, representing growth of 10.5% compared to 33,433
items dispensed in December 2025. Based on an average item value of £9.70,
this volume of activity continues to support monthly pharmacy revenue in
excess of £350,000 per month.

This sustained growth in dispensing volumes further demonstrates the
effectiveness of the Company's advanced AI triage system and state-of-the-art
robotic dispensing infrastructure, together with increasing patient demand for
both NHS and private prescription services, including through the
MedPal.clinic weight-loss platform.

Jason Drummond, CEO of MedPal AI, commented:

 

"January has delivered another excellent month of growth, with over 10% more
prescriptions dispensed than in December. This performance reflects the
scalability and resilience of our automated pharmacy model and reinforces our
confidence in the ongoing expansion of our digital health offering."

The Board continues to closely monitor trading and will provide further
updates as appropriate.

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer     Via Square1 Consulting

 Cairn Financial Advisers LLP                +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited               +44 (0) 20 3869 6080

 Bob Roberts

 Square1 Consulting                          +44 (0) 20 7929 5599

 David Bick                                  +44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages advanced robotic
dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms like Siemens and Volvo.
Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare
providers, businesses, and insurers, with potential use in insurance-linked
wellness programs to reduce premiums and drive new revenue through
institutional partnerships. The Company also has a partnership agreement with
Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEAKALESXKEFA



            Copyright 2019 Regulatory News Service, all rights reserved